Form 4 Penumbra Inc: Johanna Roberts (EVP, Gen. Counsel & Secretary) For: 15 November By Investing.com
This article reports on a Form 4 filing for Penumbra Inc, detailing that Johanna Roberts, EVP, General Counsel & Secretary, was involved in a transaction on November 15. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The article highlights this specific insider transaction for the company (PEN).
Form 4 Penumbra Inc For: Nov 15 Filed by: Shiu Lambert
This SEC Form 4 filing reports insider transactions for Lambert Shiu, Chief Accounting Officer of Penumbra Inc (PEN). It details the withholding of 830 shares to cover tax obligations from restricted stock unit (RSU) vesting on November 15, 2026, and the grant of 3,120 new RSUs on November 16, 2026. The filing also notes Shiu's total beneficial ownership of 41,676 direct common shares and 300 indirect shares via a spouse's IRA.
Penumbra revenue up 15.6% to USD 410.1M in Q3 2026
Penumbra, Inc. reported strong financial results for the third quarter ended September 30, 2026, with revenue increasing by 15.6% to $410.1 million compared to the same period in 2025. This growth was driven by significant increases in global thrombectomy and embolization and access revenues, alongside improved gross profit margins. The company also disclosed operating expenses, including acquisition-related costs for its pending acquisition by Boston Scientific Corporation, resulting in an income from operations of $50.7 million and a net income of $42.3 million.
Revenue rises 15.6% at Penumbra (PEN), but quarterly profit falls.
Penumbra, Inc. reported a 15.6% increase in third-quarter 2026 revenue, reaching $410.1 million, driven by strong growth in global thrombectomy and embolization and access revenues. Despite the revenue growth, net income fell to $42.3 million from $45.9 million in the prior year's quarter. The company will not issue full-year 2026 guidance or host a conference call due to a pending acquisition by Boston Scientific Corporation.
Penumbra, Inc. (PEN) Misses Q3 EPS by 13c
Penumbra, Inc. (PEN) reported its Q3 earnings, with an EPS of $1.07, missing the analyst estimate of $1.20 by $0.13. Despite the EPS miss, the company's revenue for the quarter came in at $410.14 million, surpassing the consensus estimate of $401.41 million.
Penumbra Reports Q3 2026 Revenue of $410.1 Million, Up 15.6%
Penumbra reported third-quarter 2026 revenue of $410.1 million, an increase of 15.6% year over year, with a net income of $42.3 million and diluted earnings per share of $1.07. The company is not providing full-year 2026 financial guidance or hosting an earnings call due to its pending acquisition by Boston Scientific. Key growth areas included global thrombectomy, U.S. venous thromboembolism, global embolization and access, and U.S. neuro revenue.
Penumbra Earnings: Solid Quarterly Results as Firm Awaits Closure of Boston Acquisition
Penumbra reported strong third-quarter results with double-digit revenue growth across both its thrombectomy and embolization/access segments. Neurovascular sales also saw significant growth. The company is currently awaiting the closure of its acquisition by Boston.
Press Release: Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Penumbra, Inc. reported its financial results for the third quarter of 2026. The report provides detailed financial figures and performance metrics for the period. This press release is a standard announcement detailing the company's fiscal health and operational achievements during the quarter.
Penumbra 3Q 2026: Revenue $410.15M, Net income $42.28M, EPS $1.07— 10-Q Summary
Penumbra reported its third-quarter 2026 financial results, with revenue increasing by 15.6% year-over-year to $410.15 million. Despite the revenue growth, net income and diluted EPS saw declines of 7.8% and 8.5% respectively. The company also announced Boston Scientific's agreement to acquire Penumbra, with the transaction expected to close in early 2027.
Penumbra Inc earnings missed by $0.13, revenue topped estimates
Penumbra Inc (NYSE: PEN) reported third-quarter earnings per share (EPS) of $1.07, missing analyst estimates by $0.13. However, the company's revenue for the quarter exceeded expectations, coming in at $410.14 million against a consensus estimate of $401.41 million. Despite the EPS miss, Penumbra's stock has seen significant growth, rising 39.06% over the last 12 months.
Penumbra Inc earnings missed by $0.13, revenue topped estimates
Penumbra Inc reported third-quarter earnings per share of $1.07, missing analyst estimates by $0.13, but exceeded revenue expectations with $410.14 million against a consensus of $401.41 million. The company's stock has seen positive growth over the past year, and its financial health is rated as "great performance" by InvestingPro.
Penumbra Inc earnings missed by $0.13, revenue topped estimates
Penumbra Inc reported third-quarter EPS of $1.07, missing analyst estimates by $0.13, but exceeded revenue expectations with $410.14M against a consensus of $401.41M. The company's stock closed at $321.97, showing a 0.24% increase over the last three months and a 39.06% rise over the past year. InvestingPro rated Penumbra Inc's financial health as "great performance."
(PEN) Movement as an Input in Quant Signal Sets
Penumbra Inc. (NYSE: PEN) shows a neutral sentiment across all time horizons, supporting sideways action with a mid-channel oscillation pattern. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with an exceptional 20.7:1 risk-reward short setup targeting 6.0% downside. Investors are advised to maintain a wait-and-see approach.
Penumbra, Inc. Estimates – NYSE:PEN
This article provides access to the financial estimates and actuals for Penumbra, Inc. (NYSE: PEN) through TradingView. Users can explore reported financial data and analyst estimates across various statements and metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform offers detailed views of income statements, balance sheets, and cash flow on both annual and quarterly bases.
Penumbra, Inc. (PEN) Stock forecasts
Argus raised its target price for Penumbra, Inc. (PEN) to $357.00. Penumbra, a US-based company, specializes in designing, manufacturing, and marketing thrombectomy and embolization devices for blood clot removal. The stock's current price is $324.96.
FDA clears Penumbra’s CAVT technology for DVT treatment By Investing.com
Penumbra Inc. announced that the U.S. Food and Drug Administration has cleared its Lightning computer assisted vacuum thrombectomy (CAVT) technology for treating deep vein thrombosis (DVT). This clearance is based on the BOLT-DVT trial, which showed 98% complete or near-complete thrombus removal with a low major adverse event rate and significant improvement in patient-reported pain relief and quality of life. The CAVT technology incorporates Lightning Flash technology to detect blood clots and blood flow using pressure- and flow-based aspiration control algorithms.
MarketBeat cites USD 367.07 target for Penumbra stock
MarketBeat reports that 17 analysts have set a consensus price target of USD 367.07 for Penumbra stock as of October 9, 2026. Penumbra's stock was trading at EUR 288.30 on October 20, 2026, with the company expected to announce its third-quarter 2026 results on November 4, 2026. The company reported a 14.90% year-over-year revenue increase in Q2 2026 but saw its operating margin narrow.
FDA clears Penumbra’s CAVT technology for DVT treatment
The FDA has granted clearance for Penumbra Inc.'s Lightning computer assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis (DVT). This clearance is based on the BOLT-DVT trial, which demonstrated that 98% of patients achieved complete or near-complete thrombus removal with a low major adverse event rate and significant improvement in patient outcomes. The technology aims to address the estimated 900,000 annual cases of venous thromboembolism in the U.S.
Penumbra wins FDA clearance for DVT treatment technology
Penumbra, Inc. announced that the FDA has cleared its Lightning computer assisted vacuum thrombectomy (CAVT) technology for treating deep vein thrombosis (DVT). This clearance is based on the BOLT-DVT trial, which showed 98% complete or near-complete thrombus removal and low adverse event rates. Experts highlight this as a significant advance in DVT treatment, offering an alternative to traditional anticoagulation.
98% of patients had all or nearly all of their clot removed in a trial. FDA cleared the device to treat deep-vein clots.
Penumbra (NYSE: PEN) has received FDA clearance for its Lightning computer-assisted vacuum thrombectomy (CAVT) technology to treat deep vein thrombosis (DVT). The clearance is based on positive results from the BOLT-DVT trial, which showed complete or near-complete clot removal in 98% of patients, alongside significant improvements in pain and quality of life. The device aims to provide a new first-line treatment option for DVT, a condition that previously relied primarily on anticoagulation.
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra, Inc. announced that its Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology has received FDA clearance for treating deep vein thrombosis (DVT). This clearance is supported by the BOLT-DVT trial, which demonstrated the safety and efficacy of CAVT, showing rapid clot removal, pain relief, and a low re-thrombosis rate. The technology aims to significantly improve patient outcomes for this serious health condition.
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra, Inc. announced that its Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology has received FDA clearance for the treatment of deep vein thrombosis (DVT). This clearance is supported by positive results from the BOLT-DVT trial, which demonstrated the safety and efficacy of CAVT in rapid clot removal, durable pain relief, and a low rate of re-thrombosis for patients with iliofemoral DVT. The trial showed 98% complete or near-complete thrombus removal and significant improvements in patient-reported outcomes.
Form 4 Penumbra Inc: Shruthi Narayan (President) For: 15 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Penumbra Inc., indicating a transaction involving Shruthi Narayan, the company's President, on October 15. The brief piece includes the stock symbol PEN and a minimal negative change, highlighting routine insider transaction news.
Penumbra stock has November 4 earnings date with USD 401.41 million forecast
Penumbra (PEN) is scheduled to report its third-quarter earnings on November 4, 2026, with analysts forecasting revenues of USD 401.41 million and earnings per share of USD 1.20. The company's stock last traded at USD 320.86, down 0.11% from the previous close, and its market capitalization stands at USD 12.6 billion with a P/E ratio of 78.84. This upcoming report will be a key event for investors, especially considering the stock's position within its 52-week trading range and its valuation compared to peers like Boston Scientific and Stryker.
Penumbra stock has November 4 earnings date with USD 401.41 million forecast
Penumbra, Inc. (NYSE: PEN) is set to report its third-quarter earnings on November 4, 2026, with analysts expecting revenues of USD 401.41 million and earnings per share of USD 1.20. The company's stock last traded at USD 320.86, showing a slight decrease from its previous close, and its market capitalization stands at USD 12.6 billion. Investors will be watching the upcoming report for financial performance and comparison against analyst estimates.
Form 4 Penumbra Inc: Shruthi Narayan (President) For: 15 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Penumbra Inc, detailing a transaction by Shruthi Narayan, the company's President, on October 15th. The brief notice provides no further details about the nature of the transaction.
MarketBeat cites USD 367.07 average target for Penumbra stock
MarketBeat reports an average 12-month price target of USD 367.07 for Penumbra stock, with a consensus of Hold from analysts. This target is 14.19 percent above the current home-exchange price. Penumbra's Q2 2026 revenue increased by 14.90 percent year-over-year, reaching USD 390.05 million, though diluted earnings per share were below consensus estimates.
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story?
Penumbra (NASDAQ:PEN), a medical technology company, is seeing its pulmonary embolism platform enhanced by recent STORM-PE clinical data. This trial connected consumer wearable step counts with traditional six-minute walk tests in patients treated with Penumbra's thrombectomy system, suggesting wearables can offer valuable real-world recovery insights. The company's diverse portfolio also includes embolization and neurovascular products, reinforcing its position in interventional medicine.
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Penumbra, Inc. announced results from a subset analysis of the STORM-PE randomized controlled trial, revealing a significant correlation between real-world daily step activity, tracked via wearable devices, and patient performance in the clinical 6-minute walk test for pulmonary embolism patients. The study found that patients treated with computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation experienced improved recovery and functional gains compared to anticoagulation alone, with wearable data complementing traditional clinical assessments. These findings, presented at VIVA and VEINS meetings, support the safety and effectiveness of CAVT and highlight the potential of wearable technology in evaluating real-world patient outcomes.
Operating cash flow per share of Penumbra, Inc. – HAN:0P8
This article provides a financial snippet for Penumbra, Inc. (HAN:0P8) listed on the Hannover Stock Exchange. Specifically, it shows the operating cash flow per share, though the actual value is not displayed in the provided content. The page also outlines various features and resources offered by TradingView.
Penumbra stock gets fresh STORM-PE data catalyst
Penumbra (PEN) stock is receiving a fresh catalyst from new STORM-PE trial data, which expanded recovery evidence for its medical devices. While the company's second-quarter revenue grew by 14.9%, net profit declined by 23.1%. RBC Capital maintained a Hold rating with a price target of USD 374.00, citing potential risks from an acquisition by Boston Scientific and regulatory approvals.
In a lung-clot study, fitness-watch steps lined up with clinic walking tests
Penumbra (NYSE: PEN) announced results from a subset analysis of its STORM-PE trial, revealing a significant correlation between daily activity recorded by wearable devices and 6-minute walk test performance in pulmonary embolism patients. The study found that computer assisted vacuum thrombectomy (CAVT) combined with anticoagulation led to improved right ventricular recovery and functional improvement, including increased walking ability. Additionally, an interim analysis of the STRIKE-PE trial further supports CAVT's safety and effectiveness, showing sustained one-year functional and quality-of-life benefits for PE patients.
Penumbra (PEN) Highlights Wearable Device Data Linking Activity to Recovery in Pulmonary Embolism Trial
Penumbra Inc (NYSE: PEN) announced findings from its STORM-PE trial, showing that wearable device data linked increased physical activity to better recovery in pulmonary embolism patients treated with computer-assisted vacuum thrombectomy (CAVT). The company's stock is considered approximately 6.2% undervalued with a strong GF Score of 89/100, though insider selling and mixed guru activity suggest some caution. Interim data from the STRIKE-PE trial also supports the safety and efficacy of their CAVT systems.
Behavioral Patterns of PEN and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Penumbra Inc. (NYSE: PEN), providing insights from AI models. It highlights a neutral near- and mid-term outlook with a long-term positive bias, presenting specific trading strategies and multi-timeframe signal analysis. The report also details current support and resistance levels, as well as risk-reward setups for potential trades.
Boston Scientific keeps Penumbra deal on track as Penumbra stock costs EUR 284.00
Boston Scientific's planned acquisition of Penumbra remains on track for completion by year-end 2026, despite Penumbra reporting acquisition-related expenses and no full-year financial guidance. Penumbra's second-quarter revenue grew by 14.90 percent to USD 390.05 million, but diluted earnings per share missed consensus estimates. Penumbra stock was trading at EUR 284.00 at Lang & Schwarz.
Penumbra, Inc. (PEN) Stock forecasts
This article from Yahoo Finance is an empty placeholder page that was meant to display stock forecasts for Penumbra, Inc. (PEN). However, it indicates an error in data retrieval and contains no actual content regarding the stock. The page primarily consists of navigation elements, advertisements, and disclaimers.
Revenue per share of Penumbra, Inc. – HAN:0P8
This page provides financial data for Penumbra, Inc. (HAN:0P8) on the Hannover Stock Exchange, specifically focusing on its revenue per share. The article highlights the "Period," "Value," "Change," and "Change %" metrics for this financial indicator.
Penumbra stock breaks below 50-day average
Penumbra (ISIN US70975L1070) stock recently fell below its 50-day moving average, trading at USD 318.14 against an average of USD 321.74. This occurred despite the company reporting a 14.90% increase in second-quarter revenue to USD 390.05 million, surpassing analyst expectations. However, adjusted earnings per share missed estimates, coming in at USD 0.88 against a USD 1.16 consensus, indicating that while sales momentum is strong, earnings execution is a key concern for investors.
Average basic shares outstanding of Penumbra, Inc. – HAN:0P8
This article provides financial data for Penumbra, Inc. (HAN:0P8) traded on the Hannover Stock Exchange. It specifically focuses on the average basic shares outstanding, indicating a financial metric for the company. The page also lists various resources and sections related to market data and financial analysis tools.
Current ratio of Penumbra, Inc. – HAN:0P8
This article displays the current ratio for Penumbra, Inc. (HAN:0P8) on the TradingView platform. It shows that for the specified period, the value, change, and percentage change in the current ratio are not available, indicated as "No trades." The page provides financial information for the company listed on the Hannover Stock Exchange.
The Technical Signals Behind (PEN) That Institutions Follow
This article analyzes Penumbra Inc. (NYSE: PEN) using AI models, identifying a neutral near and mid-term outlook with a long-term positive bias. It highlights an exceptional risk-reward setup targeting a 7.9% gain, and presents specific institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Penumbra, Inc. (PEN) Stock Analysis: Evaluating A 13.93% Upside Potential
Penumbra, Inc. (PEN) is a medical devices company with a market cap of $12.51 billion, showing robust revenue growth and strong profitability. Analysts are cautiously optimistic, with an average target price suggesting a 13.93% upside potential. The company's strategic focus on innovation and expanding product offerings make it an intriguing opportunity for investors looking for capital appreciation in the healthcare sector.
Penumbra Inc. stock trades near 317 dollars as investors weigh growth and valuation
Penumbra Inc. stock is trading around USD 317.60, reflecting strong growth expectations and a notable double-digit performance over the past year. While current prices are about 10.6% above its modeled fair value of USD 283.93, suggesting a premium, the company's fundamentals and growth profile are seen to support this valuation. Investors are balancing this premium with the company's strong price momentum and its position in the large-cap healthcare segment.
Penumbra Inc. stock holds near 315 dollars as growth expectations stay high
Penumbra Inc. stock is trading around $315.79 on the New York Stock Exchange, reflecting strong growth expectations. The company reported a non-GAAP EPS of $3.63, up 36.47% year-on-year, with analysts projecting further EPS growth of 32.46% and revenue growth of 15.96% for the next year. A previous corporate action offered shareholders $374.00 per share or Boston Scientific shares, suggesting a potential upside from the current trading price.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. (PEN) is poised for growth due to its robust product portfolio expansion and successful international presence. However, the company faces operational risks from unfavorable foreign exchange rates and a rising expense base that outpaces revenue growth. Despite these challenges, its thrombectomy technology and international sales continue to be strong tailwinds.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. (PEN) is poised for growth due to its expanding product portfolio and international market penetration, despite potential headwinds from foreign exchange fluctuations and a rising expense base. The company's recent advancements in thrombectomy technology and FDA clearances are significant tailwinds, but increased operational costs and macroeconomic sensitivities present challenges.
Mechanical Clot Engagement Option for CAVT Thrombectomy Now Available
Penumbra has launched Link, a new clot capture device designed to enhance arterial thrombus removal when used with its Lightning Bolt technology. Link mechanically engages and holds clots, integrating with computer-assisted vacuum thrombectomy (CAVT) to improve clot extraction, especially in challenging cases. This advancement aims to provide physicians with more flexibility, improve procedural efficiency, and ultimately lead to more effective patient care.
Penumbra (BSP:P2NB34) Loans Receivable : R$0 Mil (As of Jun. 2026)
Penumbra (BSP:P2NB34) reported R$0 Mil in Loans Receivable as of June 2026. GuruFocus rates Penumbra with a GF Score™ of 21/100 and considers it "Fairly Valued" with a GF Value™ of R$56.70. The article highlights that the stock trades slightly below its estimated fair value and has one warning sign.
Penumbra Inc (BSP:P2NB34) Stock Earnings Transcripts
This page provides a comprehensive list of earnings call transcripts and conference transcripts for Penumbra Inc (BSP:P2NB34), a medical devices company. It includes transcripts from various quarterly earnings calls and presentations at healthcare conferences, dating back to 2018. The page also displays key financial metrics for Penumbra Inc.
Penumbra Inc Stock Operating Data
This GuruFocus.com article provides operating data for Penumbra Inc (BSP:P2NB34), including its stock price, P/E ratio, market capitalization, and enterprise value. It notes that operating data is not available for annual or quarterly periods. The article also highlights a medium warning sign detected by GuruFocus for the stock.